Hormonal Health

Cagrilintide Cagrilintide is a long-acting amylin analog that has been studied extensively in combination with semaglutide. Here is what the Phase 3 data looks like. View research notes → CJC-1295 CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH), engineered to bind albumin and extend its half-life from minutes to roughly a week. Here is what the human and animal research actually shows. View research notes → CJC-1295 (with DAC) + Ipamorelin Two peptides that target different points in the growth hormone axis are frequently studied in combination. This page covers what the research actually shows for each. View research notes → CJC-1295 No DAC + Ipamorelin CJC-1295 No DAC and Ipamorelin are studied in combination because they activate two different receptor systems in the growth hormone axis, producing additive GH pulses through independent pathways. This page covers what the research shows. View research notes → GHRP-2 GHRP-2 is a synthetic hexapeptide that acts as a potent ghrelin receptor agonist, stimulating growth hormone release from the pituitary. Researchers study it for GH axis activation, diagnostic testing, and the physiological effects of ghrelin pathway stimulation. View research notes → GHRP-6 The original growth hormone releasing peptide, developed in 1984. Researchers studying the GH axis often compare GHRP-6 with its successors as a reference compound. View research notes → IGF-1 LR3 IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1, engineered to resist the binding proteins that limit native IGF-1's half-life. The research is entirely preclinical: animal models and cell culture. Here is an honest look at what that literature says. View research notes → Ipamorelin Ipamorelin is a selective growth hormone secretagogue studied for its ability to stimulate GH release without significant effects on cortisol or prolactin. Here is a look at the current research. View research notes → Melanotan Melanotan is the informal name for a family of synthetic alpha-MSH analogs originally developed for sunless tanning research. Two pharmaceutical descendants, afamelanotide (Scenesse) and bremelanotide (Vyleesi), are now FDA-approved for specific medical indications. View research notes → Melanotan II Melanotan II is a synthetic alpha-MSH analog studied for skin pigmentation, sexual function, and melanocortin receptor pharmacology. It is the precursor compound that led to the development of PT-141 (bremelanotide), which is FDA-approved for women's sexual dysfunction. View research notes → MOTS-c A peptide encoded within mitochondrial DNA, studied as a regulator of metabolic homeostasis and an exercise mimetic with potential relevance to aging and insulin sensitivity. View research notes → PT-141 (Bremelanotide) PT-141 is the only FDA-approved on-demand treatment for hypoactive sexual desire disorder in premenopausal women. Here is what the RECONNECT trial data shows, what the research limitations are, and what it costs per milligram. View research notes → Selank Selank is a synthetic heptapeptide studied primarily for anxiolytic and cognitive effects. It is approved as a nasal spray in Russia and has one published human clinical trial. Here is what the evidence shows. View research notes → Sermorelin Sermorelin is a synthetic fragment of growth hormone-releasing hormone studied for its ability to stimulate endogenous GH secretion. Researchers have examined its use in growth hormone deficiency, body composition, and age-related hormonal decline. View research notes → Tesamorelin Tesamorelin is a synthetic GHRH analog FDA-approved as Egrifta for excess visceral fat in people with HIV. Researchers also study it for liver fat reduction, metabolic health, and potential cognitive effects in populations with growth hormone dysregulation. View research notes → Tirzepatide Tirzepatide targets two incretin receptors at once, and in the trial record that has meant the largest weight reductions yet measured in a drug study, results that matter to the women comparing it against semaglutide for midlife metabolic research. Here is what the evidence actually shows, including the heart failure finding that is especially relevant to women. View research notes →